Skip to content
Donanemab
Donanemab is an antibody pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
11 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Alzheimer diseaseD000544EFO_0000249F03225——9
Central nervous system diseasesD002493HP_0002011G96.9—12——3
Brain diseasesD001927HP_0001298G93.40—12——3
DementiaD003704F03—12——3
Cognitive dysfunctionD060825G31.84—11——2
Nervous system diseasesD009422G00-G99——2——2
Neurodegenerative diseasesD019636EFO_0005772G31.9——2——2
Mental disordersD001523EFO_0000677F91.9——2——2
Neurocognitive disordersD019965F09——2——2
TauopathiesD024801——1——1
Indications Phases 2
No data
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—2————2
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameDONANEMAB
INNdonanemab
Description
Donanemab (USAN; development code LY3002813) is a biological drug in trial to slow the progression of early Alzheimer's disease. There is currently no cure or disease-modifying treatment for Alzheimer's disease. Donanemab has shown positive results in Eli Lilly and Co.’s first three trials. Donanemab was developed by the company Eli Lilly and Co, used in past and current trials as a possible source of treatment for the heterogeneous condition Alzheimer’s disease. Donanemab, also known as N3pG, is an antibody produced in mice that targets an abnormal protein, amyloid beta (Aβ). Whilst the cause of Alzheimer’s disease is still unknown, advances in amyloid pathology have discovered a likely relationship between the quantity of Aβ peptides and the development of Alzheimer's disease. Aβ peptides are deposited in the brain and when in excess will bind together to create a protein plaque. Donanemab targets this protein plaque, clearing the excess protein which causes a burden in the brain.
Classification
Antibody
Drug classmonoclonal antibodies
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID1931944-80-7
RxCUI—
ChEMBL IDCHEMBL4297245
ChEBI ID—
PubChem CID—
DrugBank—
UNII ID1ADB65P1KK (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 331 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details